Finance Watch: Scorpion Spinout Antares Launches With $177m For Precision Medicines
After Billions Invested, CDMO National Resilience Slims Down
Private Company Edition: Antares’ lead asset will enter the clinic in 2026 after Lilly committed up to $2.5bn for Scorpion’s Phase I/II PI3Kα inhibitor STX-478. Also, Amplify raised $200m for its first biotech VC fund and Mosanna raised an $80m series A round, among other financings.
